PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-3.61%
Negative ROE while Drug Manufacturers - Specialty & Generic median is -0.77%. Seth Klarman would investigate if capital structure or industry issues are at play.
-2.78%
Negative ROA while Drug Manufacturers - Specialty & Generic median is -1.51%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-2.32%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is -0.63%. Seth Klarman would investigate whether a turnaround is viable.
36.46%
Gross margin 75-90% of Drug Manufacturers - Specialty & Generic median of 44.17%. John Neff would look for incremental cost improvements.
-48.85%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
-65.05%
Negative net margin while Drug Manufacturers - Specialty & Generic median is -1.08%. Seth Klarman would see if cost cuts or revenue growth can fix losses.